muscle fibre necrosis and the accumulation of lymphocytes in lymphorrhagic areas.
As in many immunological or autoallergic disorders, it is the change at tissue level which is important but the associated release of autoantibodies is easier to study. These autoantibodies may in this case include antinuclear factor and thyroid antibodies (Wright & Kerr 1967) , and the association of myasthenia gravis with evidence of a more widespread immune disorder is not uncommon.
Autoantibody which reacts with peripheral muscle is detectable by fluorescent tests in the blood of over a third of patients with myasthenia gravis and in almost every case in which a tumour is present. The muscle-reacting antibody also reacts with thymic epithelial or 'myoid' cells, and absorption with thymus abolishes its muscle reactivity (van der Geld & Strauss 1966) . The cross-reaction with muscle may therefore be a side-effect of an antibody response to disease or destruction of the thymus. This view is supported by the histology of the thymoma, which in these cases is always of the epithelial cell variety, arising in a type of cell which, in its early development, often resembles striated muscle. The cross-striated appearance of the similar myoid cells in the thymus of the turtle has been beautifully demonstrated by Strauss et al. ( 1966) . If myasthenia gravis is an autoallergic disorder it should be possible to provoke a similar reaction in animals and this has now been achieved by Goldstein & Whittingham (1966) . Guinea-pigs which were immunized, either with thymus or with skeletal muscle, developed many of the features of myasthenia gravis, with a demonstrable neuromuscular block, lymphocytic collections round Hassall's corpuscles, and a circulating antibody to thymic epithelial cells which crossreacted with skeletal muscle.
The circulating antibody in myasthenia gravis does not, however, attach to the motor endplate itself and is not a constant feature of the human disease. This suggests that more than one factor must be concerned or else that the antibody released into the circulation is unimportant. Not infrequently, the infant born of a myasthenic mother may have transient neonatal myasthenia, and it has often been argued that this must be due to a circulating factor. Yet there are cases in which neither the mother nor the infant has detectable autoantibodies in the blood (Oosterhuis et al. 1966 ). If there is a humoral factor which crosses the placenta it does not appear to be muscle-binding antibody of the commonly accepted type.
In opposition to the view that myasthenia gravis is an autoallergic disease it has been argued that symptoms should be more consistently reversible by thymectomy, especially in those cases with circulating antibodies. This ignores the effects of established muscle atrophy and endplate disease, which may not always be reversible even if they are successfully arrested. Quite apart from this the response to treatment may differ when certain distinctive clinical or laboratory features are present, as in those male patients whose symptoms are limited to the extraocular muscles (Parkes & McKinna 1966) . Perhaps these patients represent a separate disease entity.
A great deal about myasthenia gravis remains to be explained. From the practical standpoint, the circulating antibody provides a useful marker of the disease, especially in those cases which are due to tumour. When it is present, an immune disorder of the thymus may be presumed even if, radiologically, this organ is normal in size. When it is absent, myasthenia gravis may still be severe but it is very unlikely to be associated with a thymoma. 
Radiotherapy of Thymic Tumours in Myasthenia Gravis
As early as 1916 Ewing had reported a case in which a thymic tumour responded well to large doses of irradiation. Subsequently several other workers reported good results with radiotherapy, but the first to mention a thymic tumour associated with myasthenia gravis being treated by means of irradiation was Pierchalla (1921) . Subsequently, surgical excision of thymic tumours became a practical proposition, and there were reports of clinical improvement, following operation, of those patients with myasthenia gravis. Keynes (1949) reported a frequent deterioration in the myasthenic state following primary surgery of thymic tumours. On occasions, the relapse was severe and some patients died post-operatively in myasthenic crisis.
Blalock (1944) reported that myasthenic patients with a tumour derived more benefit from excision than those patients without a tumour. Keynes (1949) did not confirm this finding and emphasized that the more serious the disease, the more difficult the operation was likely to be. As a result, he advocated pre-operative irradiation of the tumour followed approximately 2-3 months later by excision. A by-product of this policy has been a reduction in the incidence of pleural seeding that occurs following surgical removal of the tumour.
The histology of thymic tumours is variable, but all show the characteristic presence of lymphatic tissue to a greater or lesser extent. This tissue exhibits a high degree of radiosensitivity and reported cases of thymic tumours disappearing after doses as low as 1,500 rads are undoubtedly due to the response of the lymphatic element of the tumour. The epithelial cells of the tumour do not display this same degree of radio-sensitivity and it is probable that doses in the region of 5,000-6,000 rads are necessary to ensure their elimination. Unfortunately, the mediastinum does not tolerate high dosage irradiation well and doses of the order of 6,000 rads given to the necessarily large volume to be treated in the mediastinum would result in an intolerably high morbidity rate.
In treating these tumours it is necessary to irradiate not only the known anatomical extent of the normal thymic gland, but also the whole volume of the tumour, as demonstrated by radiographic investigations. The level of the 6th cervical vertebra, may be taken as the upper limit of the cervical extension of the two lobes. The thoracic portion lies in the anterior part of the superior mediastinum and extends down to the level of the 4th costal cartilage. It is in intimate relationship with the pericardium, the arch of the aorta and the great blood vessels. Practically all thymic tumours are found in the anterior mediastinum, but they do vary considerably in position and may at times be found as low down as the diaphragm.
The successful treatment of myasthenic patients with a thymic tumour is very much the result of a combined team effort. Preliminary investigations may be carried out as an outpatient. Then the patient should be admitted to hospital a few days before the start of treatment, to allow an accurate assessment of his exact requirements of neostigmine, and also to obtain a base line for his normal temperature and pulse readings. This base line is one of the most important guides that the radiotherapist has to control the treatment. Williams (1952) gave a comprehensive account of the first series of myasthenic patients with thymic tumours to be treated with super-voltage irradiation and laid the foundations for our present experience. The bounds of the volume to be treated will be dictated by the radiographic investigations which define the limits of the tumour. Accuracy in planning of this treatment is essential, to limit as far as possible the total volume to be irradiated, which thereby reduces the risk of subsequent complications. On average, it is necessary to treat a volume 15 cm long and the arrangement of the treatment fields used will, to some extent, be dictated by the size and shape of the patient. Usually a single anterior and two posterior oblique fields give a satisfactory dose distribution to the tumour. The plan should be to give a tumour dose of 4,000 rads in 4-5 weeks, using full fractionation with megavoltage irradiation. The overall timing cannot be rigid as the daily dose prescribed for the patient must be controlled by a careful clinical assessment of his reaction to the treatment.
Complications
Radiation-induced pneumonitis is a hazard that accompanies large-volume irradiation of lung, especially when taken to a high dose. In the presence of infection this may progress to pulmonary fibrosis. The fact that patients suffering from myasthenia gravis have an inherent liability to chest infections makes this complication all the more serious. Radiation-induced mediastinitis is a serious complication, not often seen when the mediastinum is irradiated for other conditions. It can be the heralding sign of what may eventually lead to irradiation pericarditis. The whole question of radiation carditis is discussed at length by Jones (1960) who points out that cardiac complications have seldom been reported when doses as high as 5,000-6,000 rads have been received by the heart in the course of treatment of carcinoma of the cesophagus. Thymic tumours lying in close proximity to the heart at times infiltrate the pericardium and even the myocardium, yet the tumours themselves rarely produce an effusion. Following radical irradiation of thymic tumours, Jones (1960) quotes an incidence of 7% of patients developing pericarditis.
It has been noted in other conditions when the pericardium is invaded by neoplastic disease, that a pericarditis is liable to develop. This would appear to be the main predisposing cause, but a further factor may be that the pericarditis is precipitated by the pneumonitis of the adjacent tissues. There may be complete reabsorption of the resultant effusion but there is a risk of fibrous constriction of the pericardium developing.
Management ofTreatment
The patient's daily treatment is arranged at a time shortly after a dose of neostigmine so that his muscular power will be at its optimum and he will be able to co-operate fully. On the first day, a tumour dose of not more than 100 rads should be given, as initially the myasthenic symptoms may be aggravated by the treatment. Occasionally, a myasthenic crisis is precipitated with the onset of radiotherapy but more usually, there is only a temporary deterioration in the condition. It is necessary for the radiotherapist to see the patient each day before treatment is prescribed, and the dose of neostigmine has to be adjusted according to his condition. If there has been no untoward effect from the first treatment, and the temperature and pulse charts remain steady, it is safe to proceed with the treatment and gradually increase the given dose. Eventually, a tumour dose of 200 rads a day will be given and this should not be exceeded. This gradual increase in dosage, building up to the full planned daily dose of 200 rads, is the explanation for the treatment time being extended from four to five weeks in most instances.
It is unusual for radiation pneumonitis to develop during treatment and it is most commonly seen about 4-6 weeks after treatment is completed. Breathing exercises are given daily and if the patient should develop a chest infection it is most important that it should be treated by an appropriate antibiotic and a maintenance dose given until the completion of the radiotherapy. Failure to do this is more likely to result in any subsequent radiation pneumonitis progressing to pulmonary fibrosis. The symptoms of mediastinitis, however, do become apparent during the course of radiotherapy. The first intimation of trouble is usually noted from careful examination of the temperature chart. There will be some pyrexia, in the region of 100-101°F, and there will be a disproportionate rise in the pulse rate. The patient will feel unwell and may complain of retrosternal discomfort, which radiates to his shoulder. This is the picture of a potentially dangerous situation and should never be ignored. Treatment must be suspended until the patient is symptom free and the temperature and pulse rates have returned to normal. Not before then is it safe to proceed with the treatment.
Occasionally, thymic tumours are associated with a hypoplastic marrow, and if it is noted that the patient has a tendency to low blood counts before the start of treatment, an especially close watch must be kept on this.
After the first two weeks of treatment and subsequently after each further additional 500 rads have been given to the tumour, the response of the tumour mass should be reassessed radiographically. The reason for this is the desirability to reduce the total volume of tissue being irradiated so that the risk of inducing radiation changes in healthy tissues is diminished.
The Effect ofRadiotherapy In the initial stages of the course of radiotherapy there may be some deterioration in the myasthenic state but towards the end of treatment there should be improvement; this will be reflected by the patient requiring a lower dose of neostigmine to control his myasthenia. It is difficult to analyse objectively the results of treatment in the absence of any controlled series. What is indisputable is the fairly consistent good response of the tumours to the radiotherapy. Added to this, there is a reduced incidence of malignancy developing in patients whose operation has been preceded by a course of irradiation. As far as the myasthenia is concerned the response is indeed variable but remissions of many years without the aid of drugs following treatment are by no means unknown. It has been suggested by Hale & Scowen (1967) that the degree of improvement following radiotherapy is not beyond the bounds of that which might be expected from a spontaneous remission; they also suggest that the complete rest in hospital together with intensive medical attention may be an important factor in the good response of these patients. However, until a controlled trial on this condition has been run it is only possible to give a clinical impression of the response, and this suggests that the benefits to the patient by far outweigh any long-term sideeffects of treatment.
